Company: OCEA
Filing Date: 2025-02-14
Form Type: PRE 14A
Source: 0001493152-25-006994
Chunk: 34

Company: Ocean Biomedical, Inc.
Filing Date: 2025-02-14
Form: PRE 14A
Chunk 34
---
 Common Stock under the low end, high end and midpoint of the proposed range of reverse stock split ratios, without giving effect to any adjustments for fractional shares of Common Stock, as of February 7, 2025 (and without giving effect to the Authorized Share Increase):

| Status                        |     | Number of  
 Shares     
 of         
 Common     
 Stock      
 Authorized |             |     | Number of   
 Shares      
 of          
 Common      
 Stock       
 Issued and  
 Outstanding |            |     | Number of    
 Shares       
 of           
 Common       
 Stock        
 Authorized   
 but Unissued |             |
| Pre-Reverse Stock Split       |     |            | 300,000,000 |     |             | 64,106,318 |     |              | 235,893,682 |
| Post-Reverse Stock Split 1:2  |     |            | 300,000,000 |     |             | 32,053,159 |     |              | 267,946,841 |
| Post-Reverse Stock Split 1:12 |     |            | 300,000,000 |     |             |  5,342,193 |     |              | 294,657,807 |
| Post-Reverse Stock Split 1:25 |     |            | 300,000,000 |     |             |  2,564,252 |     |              | 297,435,747 |

| 30 |

We maintain a Stock Incentive Plan (the “Plan”) pursuant to which we have granted stock options and restricted shares that are presently outstanding, and additional equity incentive compensation awards may be granted in the future under the Plan. Pursuant to the terms of the Plan, the Board of Directors or a committee thereof, as applicable, will adjust the number of shares available for future grant under the Plan, the number of shares underlying outstanding awards, the exercise price per share of outstanding stock options and other terms of outstanding awards issued pursuant to the Plan to equitably reflect the effects of the reverse stock split.

In addition, proportionate adjustments will be made to the per share exercise price of all outstanding warrants to purchase shares of our Common Stock, as well as to the numbers of each.

If the proposed reverse stock split is implemented, it will increase the number of our stockholders who own “odd lots” of fewer than 100 shares of Common Stock. Brokerage commission and other costs of transactions in odd lots are generally higher than the costs of transactions of more than 100 shares